525 related articles for article (PubMed ID: 7695230)
21. Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study.
Ułas J; Weihmuller FB; Brunner LC; Joyce JN; Marshall JF; Cotman CW
J Neurosci; 1994 Nov; 14(11 Pt 1):6317-24. PubMed ID: 7965038
[TBL] [Abstract][Full Text] [Related]
22. Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures.
Carvey PM; Ptak LR; Nath ST; Sierens DK; Mufson EJ; Goetz CG; Klawans HL
Exp Neurol; 1993 Mar; 120(1):149-52. PubMed ID: 8097475
[TBL] [Abstract][Full Text] [Related]
23. [Study of the pre and post-synaptic dopaminergic system by DaTSCAN/IBZM SPECT in the differential diagnosis of parkinsonism in 75 patients].
Vaamonde J; Ibáñez R; García AM; Poblete V
Neurologia; 2004; 19(6):292-300. PubMed ID: 15199417
[TBL] [Abstract][Full Text] [Related]
24. The human substantia nigra and ventral tegmental area. A neuroanatomical study with notes on aging and aging diseases.
van Domburg PH; ten Donkelaar HJ
Adv Anat Embryol Cell Biol; 1991; 121():1-132. PubMed ID: 2053466
[TBL] [Abstract][Full Text] [Related]
25. Delayed plasticity of the mesolimbic dopamine system following neonatal 6-OHDA lesions.
Frohna PA; Neal-Beliveau BS; Joyce JN
Synapse; 1997 Mar; 25(3):293-305. PubMed ID: 9068128
[TBL] [Abstract][Full Text] [Related]
26. Neuronal loss in the substantia nigra in patients with Alzheimer's disease and Parkinson's disease in relation to extrapyramidal symptoms and dementia.
Rinne JO; Rummukainen J; Paljärvi L; Säkö E; Mölsä P; Rinne UK
Prog Clin Biol Res; 1989; 317():325-32. PubMed ID: 2602422
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia.
Allen AM; MacGregor DP; Chai SY; Donnan GA; Kaczmarczyk S; Richardson K; Kalnins R; Ireton J; Mendelsohn FA
Ann Neurol; 1992 Sep; 32(3):339-44. PubMed ID: 1416803
[TBL] [Abstract][Full Text] [Related]
28. The degeneration of dopamine neurons in Parkinson's disease: insights from embryology and evolution of the mesostriatocortical system.
Vernier P; Moret F; Callier S; Snapyan M; Wersinger C; Sidhu A
Ann N Y Acad Sci; 2004 Dec; 1035():231-49. PubMed ID: 15681811
[TBL] [Abstract][Full Text] [Related]
29. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.
Kish SJ; Shannak K; Hornykiewicz O
N Engl J Med; 1988 Apr; 318(14):876-80. PubMed ID: 3352672
[TBL] [Abstract][Full Text] [Related]
30. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.
O'Brien JT; Colloby S; Fenwick J; Williams ED; Firbank M; Burn D; Aarsland D; McKeith IG
Arch Neurol; 2004 Jun; 61(6):919-25. PubMed ID: 15210531
[TBL] [Abstract][Full Text] [Related]
31. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
Frohna PA; Rothblat DS; Joyce JN; Schneider JS
Synapse; 1995 Jan; 19(1):46-55. PubMed ID: 7709343
[TBL] [Abstract][Full Text] [Related]
32. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine.
Thibaut F; Faucheux BA; Marquez J; Villares J; Menard JF; Agid Y; Hirsch EC
Brain Res; 1995 Sep; 692(1-2):233-43. PubMed ID: 8548309
[TBL] [Abstract][Full Text] [Related]
33. Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease.
de la Monte SM; Wells SE; Hedley-Whyte T; Growdon JH
Ann Neurol; 1989 Sep; 26(3):309-20. PubMed ID: 2802531
[TBL] [Abstract][Full Text] [Related]
34. Immunocytochemical quantification of tyrosine hydroxylase at a cellular level in the mesencephalon of control subjects and patients with Parkinson's and Alzheimer's disease.
Kastner A; Hirsch EC; Herrero MT; Javoy-Agid F; Agid Y
J Neurochem; 1993 Sep; 61(3):1024-34. PubMed ID: 8103078
[TBL] [Abstract][Full Text] [Related]
35. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?
Rogers J; Mastroeni D; Leonard B; Joyce J; Grover A
Int Rev Neurobiol; 2007; 82():235-46. PubMed ID: 17678964
[TBL] [Abstract][Full Text] [Related]
36. Reformation of the nigrostriatal pathway by fetal dopaminergic micrografts into the substantia nigra is critically dependent on the age of the host.
Bentlage C; Nikkhah G; Cunningham MG; Björklund A
Exp Neurol; 1999 Sep; 159(1):177-90. PubMed ID: 10486186
[TBL] [Abstract][Full Text] [Related]
37. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
[TBL] [Abstract][Full Text] [Related]
38. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.
Chinaglia G; Alvarez FJ; Probst A; Palacios JM
Neuroscience; 1992 Jul; 49(2):317-27. PubMed ID: 1436470
[TBL] [Abstract][Full Text] [Related]
39. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.
Mogi M; Kondo T; Mizuno Y; Nagatsu T
Neurosci Lett; 2007 Feb; 414(1):94-7. PubMed ID: 17196747
[TBL] [Abstract][Full Text] [Related]
40. Dopamine and acetylcholine cell density in the neuroleptic responsive (NR) and neuroleptic nonresponsive (NNR) lines of mice.
Hitzemann R; Qian Y; Hitzemann B
J Pharmacol Exp Ther; 1993 Jul; 266(1):431-8. PubMed ID: 8101223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
